Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 11/20 | 0.62 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12735664 | 0.81 | MC4R (0.43) | P2RX7SLC6A4MC4R | |
| SCHEMBL19304383 | 0.80 | IDO1 (0.46) | P2RX7CTSSCTSKMC4R | |
| SCHEMBL12716754 | 0.79 | P2RX7 (0.73) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL15531935 | 0.76 | P2RX7 (0.69) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL16027856 | 0.76 | P2RX7 (1.00) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL30991235 | 0.76 | P2RX7 (0.69) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL8427502 | 0.76 | P2RX7 (0.69) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL22904343 | 0.76 | P2RX7 (0.69) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL17835245 | 0.76 | P2RX7 (0.63) | P2RX7CTSSCTSKSLC6A2SLC6A4 | |
| SCHEMBL28761560 | 0.76 | P2RX7 (0.54) | P2RX7CTSSCTSKSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035310-A1 | Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels | TRPV1, TRPV5, TRPA1 | P2RX7 123/4885CTSS 2263/4885CTSK 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.